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ABSTRACT
OBJECTIVES
To derive and validate a risk prediction equation to 
estimate the short term risk of death, and to develop a 
classification method for frailty based on risk of death 
and risk of unplanned hospital admission.
DESIGN
Prospective open cohort study.
PARTICIPANTS
Routinely collected data from 1436 general practices 
contributing data to QResearch in England between 
2012 and 2016. 1079 practices were used to develop 
the scores and a separate set of 357 practices to 
validate the scores. 1.47 million patients aged 65-100 
years were in the derivation cohort and 0.50 million 
patients in the validation cohort.
METHODS
Cox proportional hazards models in the derivation 
cohort were used to derive separate risk equations 
in men and women for evaluation of the risk of death 
at one year. Risk factors considered were age, sex, 
ethnicity, deprivation, smoking status, alcohol intake, 
body mass index, medical conditions, specific drugs, 
social factors, and results of recent investigations. 
Measures of calibration and discrimination were 
determined in the validation cohort for men and 
women separately and for each age and ethnic group. 
The new mortality equation was used in conjunction 
with the existing QAdmissions equation (which 
predicts risk of unplanned hospital admission) to 
classify patients into frailty groups.
MAIN OUTCOME MEASURE
The primary outcome was all cause mortality.
RESULTS
During follow-up 180 132 deaths were identified in 
the derivation cohort arising from 4.39 million person 
years of observation. The final model included terms 
for age, body mass index, Townsend score, ethnic 
group, smoking status, alcohol intake, unplanned 
hospital admissions in the past 12 months, atrial 
fibrillation, antipsychotics, cancer, asthma or 
chronic obstructive pulmonary disease, living in a 
care home, congestive heart failure, corticosteroids, 
cardiovascular disease, dementia, epilepsy, 
learning disability, leg ulcer, chronic liver disease 
or pancreatitis, Parkinson’s disease, poor mobility, 
rheumatoid arthritis, chronic kidney disease, type 1 
diabetes, type 2 diabetes, venous thromboembolism, 
anaemia, abnormal liver function test result, high 
platelet count, visited doctor in the past year with 
either appetite loss, unexpected weight loss, or 
breathlessness. The model had good calibration and 
high levels of explained variation and discrimination. 
In women, the equation explained 55.6% of the 
variation in time to death (R2), and had very good 
discrimination—the D statistic was 2.29, and Harrell’s 
C statistic value was 0.85. The corresponding values 
for men were 53.1%, 2.18, and 0.84. By combining 
predicted risks of mortality and unplanned hospital 
admissions, 2.7% of patients (n=13 665) were 
classified as severely frail, 9.4% (n=46 770) as 
moderately frail, 43.1% (n=215 253) as mildly frail, 
and 44.8% (n=223 790) as fit.
CONCLUSIONS
We have developed new equations to predict the 
short term risk of death in men and women aged 
65 or more, taking account of demographic, social, 
and clinical variables. The equations had good 
performance on a separate validation cohort. The 
QMortality equations can be used in conjunction with 
the QAdmissions equations, to classify patients into 
four frailty groups (known as QFrailty categories) to 
enable patients to be identified for further assessment 
or interventions.
Introduction
NHS England (the commissioning body for the English 
National Health Service) recently announced that 
from July 2017 all general practices in England will be 
contractually obliged to identify patients with moderate 
and severe frailty as part of the new General Medical 
Service contract. This is particularly challenging 
because frailty is a relatively new concept that does 
not have an agreed definition. Current approaches 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Recent NICE guidance on multiple morbidities has highlighted the need to develop 
new robust equations to identify patients in primary care with reduced life expectancy 
so that relevant assessments and interventions can be targeted appropriately
Existing equations to predict risk of death are based on biased samples, are 
insufficiently powered, fail to handle missing data appropriately, are poorly 
reported, or have poor performance to the extent that NICE has been unable to 
make a positive recommendation on any tool
WhAT ThIS STudy AddS
A new equation (QMortality) quantified absolute risk of death within the next 
one year in people aged 65 or more, taking account of demographic, social, and 
clinical variables
QMortality provides a valid measure of absolute risk of death in the general 
population of older patients, as shown by its performance in a separate 
validation cohort
QMortality can be used in conjunction with the QAdmissions equation for 
unplanned hospital admissions to classify patients into four QFrailty groups to 
enable identification for focused assessments and interventions
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to defining frailty involve identifying patients with a 
collection of diagnoses, symptoms, and social factors.1 2 
These factors may be combined into a frailty score. 
This score is then used to identify patients at risk of 
important or preventable outcomes such as unplanned 
hospital admissions or death in the near future.
Although recent guidance from the National 
Institute for Health Care and Excellence on multiple 
morbidities3 has recommended tools to predict risk of 
unplanned hospital admissions,4 5 NICE was unable 
to identify any equations to reliably predict all cause 
mortality. NICE identified 41 studies that validated an 
equation to predict all cause mortality, all of which 
had major limitations. For example, some equations 
had been developed for purposes other than to predict 
all cause mortality.2 Other limitations were omitting 
key determinants of death, such as age and sex; giving 
equal weighting to all component factors within an 
equation (for example, wearing glasses could have 
equal weighting to ischaemic heart disease); using 
small unrepresentative samples; inappropriate 
handling of missing data; and poor reporting and 
poor performance of the tool in predicting death. The 
NICE guideline therefore recommended that research 
should be undertaken to develop new robust equations 
to identify patients with reduced life expectancy so 
that relevant assessments and interventions can be 
targeted appropriately.
We aimed to address the NICE research 
recommendation by developing a new equation to 
predict risk of death over a one year period among 
people aged 65 and older using a large validated 
medical research database of representative patients 
in primary care. Our secondary objective was to 
develop a definition of frailty directly based on risk 
of outcomes. Instead of creating a frailty index in the 
hope that it would predict unplanned admissions 
and all cause mortality, we decided to work the other 
way round. Starting with principled estimators of 
unplanned admissions and all cause mortality, we 
decided to develop a new classification of frailty, 
known as QFrailty. This would group people into four 
categories—severely frail, moderately frail, mildly frail, 
or fit—based on their absolute risks of an unplanned 
hospital admission or death within a year. This could 
then provide an outcomes based classification to 
improve on the electronic frailty index recommended 
by NHS England.2
Methods
Study design and data source
We undertook a cohort study in a large population of 
primary care patients in England who were registered 
with practices contributing to the QResearch database 
(version 42). All practices had to have used EMIS 
computer system for at least a year. We randomly 
allocated three quarters of the practices to the derivation 
dataset and the remainder to a validation dataset. We 
identified an open cohort of patients aged 65-100 years 
registered with practices between 1 January 2012 and 
30 September 2016. Exclusions were patients who did 
not have a valid National Health Service number and 
those who did not have a postcode related Townsend 
score (eg, patients had moved to newly built houses 
with new postcodes not yet linked to deprivation data 
or patients were homeless or did not have a permanent 
residence). We determined an entry date to the cohort 
for each patient, which was the latest of his or her 65th 
birthday, date of registration with the practice plus one 
year, date on which the practice computer system was 
installed plus one year, and beginning of the study 
period (1 January 2012). Patients were censored at the 
earliest date of death, de-registration with the practice, 
last upload of computerised data, or the study end date 
(30 September 2016).
Outcomes
Our primary outcome was all cause mortality, using 
the date of death recorded on the QResearch database. 
We chose to evaluate risk of death at one year for 
comparability with other studies and to meet the 
requirements of the research recommendation in the 
NICE guidelines. The QResearch database is linked 
at individual patient level to the hospital admissions 
data and to mortality records obtained from the Office 
for National Statistics. The records are linked using 
a project specific pseudonymised NHS number. The 
recording of NHS numbers is valid and complete for 
99.8% of QResearch patients, 99.9% for ONS mortality 
records, and 98% for hospital admissions records.4 6
Predictor variables
We examined several predictor variables (see box 1) 
based on established risk factors already included 
in the QAdmissions equation4 (which predicts risk 
of unplanned hospital admissions) and variables 
highlighted in the related literature.2 3 7-10
The number of unplanned hospital admissions in 
the previous 12 months was derived from information 
on the linked hospital records. All predictor variables 
were based on the latest coded information recorded in 
the general practice record before entry to the cohort.
Derivation and validation of the models
We developed and validated the risk prediction 
equations using established methods.10 12-15 To replace 
missing values for body mass index, smoking status, 
and alcohol intake we used multiple imputation with 
chained equations and used these values in our main 
analyses.16-19 We carried out five imputations as this 
has relatively high efficiency20 and was a pragmatic 
approach accounting for the size of the datasets and 
capacity of the available servers and software. We 
included all predictor variables in the imputation 
model, along with age interaction terms, the Nelson-
Aalen estimator of the baseline cumulative hazard, 
and the outcome indicator.
Cox’s proportional hazards models estimated the 
coefficients for each risk factor in men and women 
separately. We used Rubin’s rules to combine the results 
across the imputed datasets.21 We used fractional 
polynomials22 to model non-linear risk relations with 
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continuous variables (age and body mass index) using 
data from patients with recorded values to derive the 
fractional polynomial terms. Initially we fitted full 
models. We retained variables if they had an adjusted 
hazard ratio of <0.90 or >1.10 (for binary variables) 
and were statistically significant at the 0.01 level. We 
examined interactions between predictor variables and 
age at study entry and included statistically significant 
interactions in the final models.
For each variable from the final model we used the 
regression coefficients as weights, which we combined 
with the baseline survivor function at one year to derive 
risk equations.23 We estimated the baseline survivor 
function based on zero values of centred continuous 
variables, with all binary predictor values set to zero.
Validation of the models
In the validation cohort we used multiple imputation to 
replace missing values for body mass index, smoking 
status, and alcohol intake. Five imputations were done. 
We applied the risk equations for men and women 
obtained from the derivation cohort to the validation 
cohort and calculated measures of discrimination. As in 
previous studies,24 we calculated R2 values (explained 
variation where higher values indicate a greater 
Box 1: Predictor variables
•   Age (continuous variable)
•   Geographical region in England (10 regions)
•   Townsend deprivation score. This is an area level 
continuous score based on the patients’ postcode.11 
Originally developed by Townsend,11 the score 
includes unemployment (as a percentage of those 
aged 16 or more who are economically active), 
non-car ownership (as a percentage of all 
households), non-home ownership (as a percentage 
of all households), and household overcrowding. 
These variables are measured for a given area of 
approximately 120 households, through the 2011 
census, and combined to give a Townsend score for 
that area. A higher Townsend score implies a greater 
level of deprivation
•   Ethnic group (nine categories)
•   Alcohol intake (<1 unit/day, 1-2 units/day, 3-6 units/
day, 7-9 units/day, ≥9 units/day) (see www.nhs.uk/
Livewell/alcohol/Pages/alcohol-units.aspx)
•   Smoking status (non-smoker; former smoker; light, 
moderate, or heavy smoker)
•   Body mass index (continuous variable)
•   Unplanned admissions in past 12 months (0, 1, 2, or 
≥3) as recorded on the linked hospital data
•   Poor mobility (poor mobility, housebound, confined 
to chair, bedridden, requires home visit, receives 
mobility allowance)
•   Lives in a care home (nursing home or residential 
care)
•   Lives alone
•   Atrial fibrillation
•   Congestive heart failure
•   Cardiovascular disease (myocardial infarction, 
angina, stroke, or transient ischaemic attack)
•   Valvular heart disease
•   Peripheral vascular disease
•   Treated hypertension (hypertension and current 
antihypertensive treatment)
•   Chronic kidney disease (stages 4 or 5)
•   Diabetes (none, type 1, type 2)
•   Hypothyroidism
•   Hyperthyroidism
•   Cancer
•   Chronic liver disease or pancreatitis
•   Malabsorption (including Crohn’s disease, ulcerative 
colitis, coeliac disease, steatorrhea, blind loop 
syndrome)
•   Peptic ulcer (gastric or duodenal ulcer, simple or 
complicated ulcer)
•   Asthma or chronic obstructive airways disease
•   Epilepsy
•   Dementia
•   Learning disability
•   Osteoporosis
•   Fragility fracture (hip, spine, shoulder, or wrist 
fracture)
•   Parkinson’s disease or syndrome
•   Rheumatoid arthritis
•   Falls
•   Bipolar disorder or schizophrenia
•   Depression in past 12 months
•   Venous thromboembolism
•   Anaemia (haemoglobin <110 g/L)
•   Abnormal liver function test result (bilirubin, alanine 
aminotransferase, or γ glutamyltransferase more 
than three times the upper limit of normal)
•   High platelet count (>480×109/L)
•   Leg ulcer (leg, shin, ankle or foot ulcer, ischaemic 
neuropathic, arterial, or venous ulcer)
•   Blindness (registered blind or partially sighted or 
visual impairment)
•   Appetite loss in past 12 months
•   Weight loss in past 12 months (unexplained or 
abnormal weight loss)
•   Urinary incontinence in past 12 months
•   Nocturia in past 12 months
•   Urinary retention in past 12 months (acute or chronic 
retention)
•   Syncope (vasovagal symptom, faint, collapse, “funny 
turn,” drop attack) in past 12 months
•   Dizziness in past 12 months
•   Insomnia in past 12 months
•   Dyspnoea in past 12 months (breathless at rest or on 
exertion, paroxysmal nocturnal dyspnoea)
•   Hearing impairment or deafness in past 12 months
•   Loneliness in past 12 months
•   Use of anticoagulants (≥2 prescriptions in past six 
months)
•   Use of antidepressants (≥2 prescriptions in past six 
months)
•   Use of antipsychotics (≥2 prescriptions in past six 
months)
•   Use of corticosteroids (≥2 prescriptions in past six 
months)
•   Non-steroidal anti-inflammatory drugs (≥2 
prescriptions in past six months)
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proportion of variation in survival time explained by 
the model25), D statistic26 (a measure of discrimination 
that quantifies the separation in survival between 
patients with different levels of predicted risk, where 
higher values indicate better discrimination), and 
Harrell’s C statistic at one year and combined these 
across datasets using Rubin’s rules. Harrell’s C 
statistic27 is a measure of discrimination (separation) 
that quantifies the extent to which those with earlier 
events have higher risk scores. It is similar to the 
receiver operating characteristic statistic but takes 
account of the censored nature of the data. Higher 
values of Harrell’s C indicate better performance of the 
model for predicting the relevant outcome. A value of 
1 indicates the model has perfect discrimination. A 
value of 0.5 indicates that the model discrimination 
is no better than chance. We also evaluated these 
performance measures in five age groups and nine 
ethnic groups. We calculated 95% confidence intervals 
for the performance statistics to allow comparisons 
with alternative models for the same outcome and 
across different subgroups.28
We assessed calibration of the mortality score by 
comparing the mean predicted risks evaluated at one 
year with the observed risks by 10th of predicted risk. 
The observed risks were obtained using the Kaplan-
Meier estimates evaluated at one year for men and 
women. We also evaluated performance by calculating 
Harrell’s C statistics in individual general practices 
and combined the results using meta-analytical 
techniques.29
We also applied the latest version of the QAdmissions 
score to the validation cohort and calculated measures 
of discrimination for unplanned hospital admissions 
over one year.
Decision curve analysis
We used decision curve analysis in the validation 
cohort to evaluate the net benefits of the mortality 
score.30-32 This method assesses the benefits of correctly 
identifying people who will have an event compared 
with the harms from a false positive classification 
(which could, for example, lead to unnecessary distress 
or interventions). The net benefit of a risk equation 
at a given risk threshold is given by calculating the 
difference between the proportion of true positives and 
the proportion of false positives multiplied by the odds 
of the risk threshold. We calculated the net benefits 
across a range of threshold probabilities and compared 
these with alternative strategies of “intervention in 
everyone” and “intervention in no one.” In general, the 
strategy with the highest net benefit at any given risk 
threshold is considered to have the most clinical value.
Development of frailty categories
Since there is no currently accepted threshold for 
classifying high risk of death, we examined the 
distribution of predicted risks and calculated a series of 
centile values. For each centile threshold, we calculated 
the sensitivity, specificity, and positive and negative 
predictive values of death over a one year follow-up 
period. Using the latest version of the QAdmissions 
score we also examined the distribution of patients 
by their risk of unplanned hospital admission over 
one year.4 We identified unplanned admissions using 
the hospital episode statistics linked to QResearch 
as in the original paper.4 We then classified patients 
into four frailty groups based on a combination of 
their predicted risk of unplanned admission and 
their predicted risk of death over the next 12 months 
such that the proportion of patients in each group 
was broadly similar to that published elsewhere for 
the “electronic frailty score” (EFI) based on a similar 
English population.2 In the internal validation of the 
EFI score, 3% of the validation cohort were categorised 
as having severe frailty, 12% as having moderate 
frailty, 35% as having mild frailty, and 50% as fit. The 
corresponding values for the EFI external validation 
cohort were 4%, 16%, 37%, and 43%.
We repeated some analyses, restricting the validation 
cohort to those with two or more medical conditions 
who would meet the NICE broad definition of having 
multiple morbidities. The supplementary tables 
present the results. To maximise the power and also 
generalisability of the results we used all the relevant 
patients on the database. STATA (version 14) was used 
for all analyses. We adhered to the TRIPOD statement 
for reporting.33
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in the design or implementation of the study. 
Patient representatives from the QResearch advisory 
board have written the information for patients on the 
QResearch website about the use of the database for 
research. They have also advised on dissemination 
of the results, including the use of lay summaries 
describing the research and its results.
Results
Overall study population
Derivation cohort—overall, 1436 QResearch practices in 
England met our inclusion criteria, of which 1079 were 
randomly assigned to the derivation dataset, with the 
remainder (n=357) assigned to the validation cohort. 
We identified 1 471 558 patients in the derivation cohort 
aged 65-100 years. Of these, we excluded 2550 (0.2%) 
who did not have a valid NHS number and a further 
2410 (0.2%) who did not have a recorded Townsend 
score, leaving 1 466 598 for the derivation analysis.
Validation cohort—we identified 500 816 patients 
in the validation cohort aged 65-100 years. Of those, 
we excluded 505 (0.1%) who did not have a valid NHS 
number and a further 833 (0.2%) who did not have 
a recorded Townsend score, leaving 499 478 for the 
validation analysis.
Baseline characteristics
Table 1 shows the baseline characteristics of men and 
women in the derivation and validation cohorts. In the 
derivation cohort, self assigned ethnicity was recorded 
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Table 1 | Baseline characteristics of patients aged 65-100 years in derivation and validation cohorts. Values are 
numbers (percentages) unless stated otherwise
Characteristics Derivation cohort (n=1 466 598) Validation cohort (n=499 478)
Men 661 694 (45.1) 224 547 (45.0)
Mean (SD) age (years) 75.3 (8.0) 75.3 (8.0)
Mean (SD) Townsend deprivation score* −0.7 (3.0) −0.6 (2.9)
Age band (years):
 65-69 442 386 (30.2) 151 236 (30.3)
 70-74 323 574 (22.1) 110 885 (22.2)
 75-79 267 641 (18.2) 90 415 (18.1)
 80-84 208 967 (14.2) 70 640 (14.1)
 85-100 224 030 (15.3) 76 302 (15.3)
Region in England:
 East Midlands 81 431 (5.6) 31 707 (6.3)
 East of England 112 915 (7.7) 27 419 (5.5)
 London 189 005 (12.9) 69 316 (13.9)
 North east 61 255 (4.2) 19 346 (3.9)
 North west 256 504 (17.5) 83 381 (16.7)
 South central 165 438 (11.3) 81 030 (16.2)
 South east 148 212 (10.1) 36 796 (7.4)
 South west 179 601 (12.2) 75 051 (15.0)
 West Midlands 187 298 (12.8) 50 884 (10.2)
 Yorkshire and Humber 84 939 (5.8) 24 548 (4.9)
Ethnic group:
 Recorded 1 177 596 (80.3) 391 503 (78.4)
 White or not recorded 1 387 476 (94.6) 474 518 (95.0)
 Indian 18 601 (1.3) 6065 (1.2)
 Pakistani 8008 (0.5) 3160 (0.6)
 Bangladeshi 5449 (0.4) 1516 (0.3)
 Other Asian 8268 (0.6) 2731 (0.5)
 Caribbean 15 916 (1.1) 4415 (0.9)
 Black African 7953 (0.5) 2196 (0.4)
 Chinese 2957 (0.2) 907 (0.2)
 Other ethnic group 11 970 (0.8) 3970 (0.8)
Smoking status:
 Recorded 1 451 343 (99.0) 494 576 (99.0)
 Non-smoker 785 482 (53.6) 264 165 (52.9)
 Former smoker 520 517 (35.5) 179 517 (35.9)
 Light smoker 83 757 (5.7) 28 549 (5.7)
 Moderate smoker 38 971 (2.7) 13 918 (2.8)
 Heavy smoker 22 616 (1.5) 8427 (1.7)
Alcohol intake (units/day):
 Recorded 1 349 728 (92.0) 456 150 (91.3)
 Non-drinker 539 314 (36.8) 181 050 (36.2)
 <1 416 894 (28.4) 141 499 (28.3)
 1-2 182 700 (12.5) 62 769 (12.6)
 3-6 191 013 (13.0) 63 658 (12.7)
 7-9 13 455 (0.9) 4820 (1.0)
 >9 5403 (0.4) 2045 (0.4)
Unplanned hospital admissions in past 12 months:
 None 1 290 683 (88.0) 439 774 (88.0)
 1 116 749 (8.0) 39 834 (8.0)
 2 35 430 (2.4) 11 884 (2.4)
 ≥3 23 736 (1.6) 7986 (1.6)
Clinical and social characteristics:
 Poor mobility 142 924 (9.7) 55 134 (11.0)
 Living in a residential or nursing home 27 471 (1.9) 9275 (1.9)
 Atrial fibrillation 120 671 (8.2) 40 729 (8.2)
 Any cancer 162 406 (11.1) 55 175 (11.0)
 Asthma or chronic obstructive airways disease 227 226 (15.5) 76 470 (15.3)
 Congestive heart failure 57 572 (3.9) 19 749 (4.0)
 Cardiovascular disease 307 499 (21.0) 104 925 (21.0)
 Treated hypertension 628 106 (42.8) 215 567 (43.2)
 Hyperthyroidism 23 432 (1.6) 7672 (1.5)
 Hypothyroidism 134 476 (9.2) 46 172 (9.2)
 Chronic kidney disease 25 641 (1.7) 8877 (1.8)
 Type 1 diabetes 10 123 (0.7) 3348 (0.7)
 Type 2 diabetes 220 886 (15.1) 73 909 (14.8)
(Continued)
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in 80.3% (n=1 177 596), smoking status in 99.0% 
(n=1 451 343), alcohol intake in 92.0% (n=1 349 728), 
and body mass index in 90.2% (n=1 322 929). Overall, 
86.8% (n=1 273 310) had complete data for smoking 
status, alcohol intake, and body mass index. The mean 
age was 75.3 years, and 12.0% (n=175 915) of patients 
had one or more unplanned hospital admissions in 
the past 12 months, 42.8% (n=628 106) had treated 
hypertension, 21.0% (n=307 499) had cardiovascular 
disease, 15.1% (n=220 886) had type 2 diabetes, 
18.8% (n=276 001) were prescribed antidepressants, 
and 18.3% (n=268 821) were prescribed non-steroidal 
anti-inflammatory drugs (NSAIDs). The corresponding 
results for the validation cohort were similar.
Supplementary table 1 shows the patients’ 
number of medical conditions. In the derivation 
cohort, 17.3% (n=253 585) did not have any of the 
29 conditions listed, 23.9% (n=350 994) had one 
condition, and 58.8% (n=862 019) had two or more 
conditions.
Table 1 | Continued
Characteristics Derivation cohort (n=1 466 598) Validation cohort (n=499 478)
 Venous thromboembolism 59 066 (4.0) 20 275 (4.1)
 Epilepsy 21 773 (1.5) 7519 (1.5)
 Leg ulcer 41 654 (2.8) 13 957 (2.8)
 Chronic liver disease or pancreatitis 13 380 (0.9) 4587 (0.9)
 Depression in the past 12 months 114 669 (7.8) 37 749 (7.6)
  Malabsorption (Crohn’s disease, ulcerative  
colitis, coeliac disease)
19 178 (1.3) 6455 (1.3)
 Parkinson’s disease 16 101 (1.1) 5308 (1.1)
 Peptic ulcer disease 92 236 (6.3) 30 992 (6.2)
 Fragility fracture 4020 (0.3) 1015 (0.2)
 Osteoporosis 100 931 (6.9) 34 071 (6.8)
 Rheumatoid arthritis 30 628 (2.1) 10 312 (2.1)
 Learning disability 15 836 (1.1) 4982 (1.0)
 Dementia 65 828 (4.5) 22 710 (4.5)
 Bipolar disorder or schizophrenia 13 137 (0.9) 4261 (0.9)
 Hearing loss 247 928 (16.9) 81 544 (16.3)
 Cataract 204 807 (14.0) 68 571 (13.7)
 Registered blind or impaired vision 30 987 (2.1) 11 209 (2.2)
 Falls 205 672 (14.0) 69 669 (13.9)
 ≥2 medical conditions (see above) 862 019 (58.8) 292 096 (58.5)
Current prescribed drugs:
 Anticoagulants 92 484 (6.3) 31 443 (6.3)
 Antidepressants 276 001 (18.8) 96 122 (19.2)
 Antipsychotics 25 661 (1.7) 8785 (1.8)
 Corticosteroids 136 214 (9.3) 46 332 (9.3)
 Non-steroidal anti-inflammatory drugs 268 821 (18.3) 89 246 (17.9)
Symptoms or situation recorded by doctor in past 12 months:
 Appetite loss 3549 (0.2) 1106 (0.2)
 Unexplained weight loss 10 710 (0.7) 3541 (0.7)
 Dyspnoea 104 563 (7.1) 36 316 (7.3)
 Syncope 16 008 (1.1) 5445 (1.1)
 Urinary incontinence 15 022 (1.0) 4845 (1.0)
 Urinary retention 4935 (0.3) 1633 (0.3)
 Nocturia 7268 (0.5) 2517 (0.5)
 Dizziness 48 891 (3.3) 16 777 (3.4)
 Insomnia 18 187 (1.2) 6033 (1.2)
 Loneliness 1144 (0.1) 244 (0.0)
 Lives alone 8030 (0.5) 2718 (0.5)
Clinical values:
 Body mass index recorded 1 322 929 (90.2) 448 322 (89.8)
 Mean (SD) body mass index 27.3 (4.9) 27.3 (5.0)
 Full blood count recorded 1 091 839 (74.4) 376 829 (75.4)
 Platelet count recorded 1 269 085 (86.5) 432 388 (86.6)
 Liver function test result recorded 1 172 729 (80.0) 384 423 (77.0)
 Complete data† 873 765 (59.6) 285 655 (57.2)
 Complete data‡ 1 273 310 (86.8) 429 123 (85.9)
 Anaemia (haemoglobin <110 g/L) 46 766 (3.2) 16 085 (3.2)
 Abnormal liver function test result§ 29 409 (2.0) 9928 (2.0)
 High platelet count 14 010 (1.0) 4753 (1.0)
*This is an area level continuous score based on patients’ postcode. A higher Townsend score implies a greater level of deprivation.
†Complete data for all of smoking status, alcohol intake, body mass index, haemoglobin concentration, platelet count, and liver function test before 
cohort entry.
‡Complete data for imputed variables: smoking status, alcohol intake, and body mass index.
§γ glutamyltransferase, alanine aminotransferase, or bilirubin levels more than three times the upper limit of normal.
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Incidence of death
Table 2 shows the number of patients who died during 
the study period, the person years of follow-up, and the 
death rates by age and sex. Overall in the derivation 
cohort, 180 132 deaths arose from 4.39 million person 
years of follow-up. In the validation cohort, 61 446 
deaths arose from 1.49 million person years of follow-
up. In the derivation and validation cohorts 581 702 
and 197 834 people, respectively, had five or more 
years of follow-up.
Predictor variables
Table 3 shows the adjusted hazard ratios for the final 
models for women and men in the derivation cohort. 
The final model included the variables: fractional 
polynomial terms for age, fractional polynomial terms 
for body mass index, Townsend score, ethnic group, 
smoking status, alcohol intake, unplanned hospital 
admissions in the past 12 months, atrial fibrillation, 
antipsychotics, cancer, asthma or chronic obstructive 
pulmonary disease, living in a care home, congestive 
heart failure, corticosteroids, cardiovascular disease, 
dementia, epilepsy, learning disability, leg ulcer, 
chronic liver disease or pancreatitis, Parkinson’s 
disease, poor mobility, rheumatoid arthritis, chronic 
kidney disease, type 1 diabetes, type 2 diabetes, 
venous thromboembolism, anaemia, abnormal liver 
function test result, high platelet count, and visits to a 
general practitioner in the past 12 months with either 
appetite loss, unexplained weight loss, or dyspnoea 
(breathlessness). The other variables tested did not 
meet the criteria for inclusion in the final model.
The graphs in figures 1 and 2 show the adjusted 
hazard ratios in women and men, respectively, for age 
interaction terms that were statistically significant (see 
footnote in table 3). For each of these interactions, 
hazard ratios for the predictors were higher at younger 
ages compared with older ages.
Validation
Discrimination
Table 4 shows the performance of the QMortality score 
in the validation cohort for women and men at one 
year. Overall, the values for the R2, D, and C statistics 
were higher in women than in men indicating that 
the score performed better in women than in men. 
The mortality equation in women explained 55.6% 
of the variation in time to death (R2), the D statistic 
was 2.29, and Harrell’s C statistic was 0.85. The 
corresponding values for men were 53.1%, 2.18, and 
0.84. Table 4 also shows results for the latest version 
of the QAdmissions equation for predicting unplanned 
admissions (based on 160 217 unplanned admissions 
in the validation cohort over a one year period). Table 
4 shows that the performance of the QMortality score 
for predicting deaths was better than the performance 
of the QAdmissions score for predicting unplanned 
admissions.
Supplementary table 2 shows the results for the 
mortality scores by age group and ethnic group. 
Performance tended to be better in the younger age 
groups but was similar across all ethnic groups.
Figure 3 shows plots of Harrell’s C statistic for each 
general practice in the validation cohort against the 
number of deaths in each practice in women and men 
separately. The summary (average) C statistic for women 
was 0.854 (95% confidence interval 0.850 to 0.859) 
from a random effects meta-analysis. The I2 value (ie, 
the percentage of total variation in C statistic owing 
to heterogeneity between practices) was 63.2%. The 
approximate 95% prediction interval for the true C 
statistic in women in a new practice was 0.80 to 0.91. For 
men, the summary C statistic was 0.844 (95% confidence 
interval 0.839 to 0.849). The I2 value was 70.3%. The 
approximate 95% prediction interval for the true C 
statistic in men in a new practice was 0.76 to 0.92.
Supplementary table 3 shows the validation 
statistics for the mortality score among patients with 
two or more morbidities (as required by the NICE 
guideline3).
Calibration
Figure 4 displays the observed risks and mean predicted 
risks of death across each 10th of the predicted risk 
score (1 representing the lowest risk and 10 the highest 
risk). This shows that the equation was well calibrated. 
Supplementary figure 1a-e shows the calibration 
within each age group. Supplementary table 5 shows 
overall calibration by age group and ethnic group and 
for the top 2%, 10%, and 50% of predicted risk. The 
Table 2 | Number of deaths, person years of follow up, and death rate per 1000 person years of observation (95% confidence intervals) in 
derivation and validation cohort
Characteristics
Derivation cohort Validation cohort
No of deaths Person years
Death rate per 1000  
person years (95% CI) No of deaths Person years
Death rate per 1000  
person years (95% CI) 
Women 94 999 2 405 772 39.5 (39.2 to 39.7) 32 726 821 029 39.9 (39.4 to 40.3)
Men 85 133 1 981 380 43.0 (42.7 to 43.3) 28 720 672 665 42.7 (42.2 to 43.2)
Age band (years):
 65-69 17 288 1 410 337 12.3 (12.1 to 12.4) 6023 483 057 12.5 (12.2 to 12.8)
 70-74 21 599 1 022 097 21.1 (20.9 to 21.4) 7408 350 038 21.2 (20.7 to 21.7)
 75-79 29 141 829 908 35.1 (34.7 to 35.5) 9895 280 968 35.2 (34.5 to 35.9)
 80-84 37 679 605 479 62.2 (61.6 to 62.9) 12 611 203 123 62.1 (61.0 to 63.2)
 85-89 37 694 342 402 110.1 (109.0 to 111.2) 12 849 115 905 110.9 (109.0 to 112.8)
 90-94 27 061 145 561 185.9 (183.7 to 188.1) 9278 49 511 187.4 (183.6 to 191.2)
 95-100 9,670 31 368 308.3 (302.2 to 314.5) 3382 11 092 304.9 (294.8 to 315.3)
Overall 180 132 4 387 152 41.1 (40.9 to 41.2) 61 446 1 493 694 41.1 (40.8 to 41.5)
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Table 3 | Adjusted hazard ratios (95% confidence interval) for death in derivation cohort. Models also include fractional polynomial terms for age 
and body mass index
Characteristics
Adjusted hazard ratio (95% CI)
Women Men
Townsend score (5 unit increase)* 1.13 (1.11 to 1.15) 1.2 (1.18 to 1.21)
Ethnic group:
 White or not recorded 1.00 1.00
 Indian 0.89 (0.83 to 0.96) 0.78 (0.73 to 0.83)
 Pakistani 0.99 (0.89 to 1.10) 0.77 (0.70 to 0.85)
 Bangladeshi 0.92 (0.81 to 1.04) 0.79 (0.71 to 0.87)
 Other Asian 0.82 (0.72 to 0.92) 0.67 (0.59 to 0.75)
 Caribbean 0.75 (0.80 to 0.81) 0.71 (0.66 to 0.77)
 Black African 0.68 (0.59 to 0.78) 0.71 (0.63 to 0.80)
 Chinese 0.53 (0.42 to 0.68) 0.64 (0.53 to 0.78)
 Other ethnic group 0.87 (0.80 to 0.95) 0.75 (0.69 to 0.82)
Smoking status:
 Non-smoker 1.00 1.00
 Former smoker 1.18 (1.16 to 1.20) 1.18 (1.16 to 1.20)
 Light smoker 1.79 (1.74 to 1.84) 1.71 (1.66 to 1.76)
 Moderate smoker 2.07 (1.99 to 2.15) 1.90 (1.82 to 1.98)
 Heavy smoker 2.29 (2.17 to 2.41) 2.14 (2.05 to 2.24)
Alcohol intake (units/day):
 Non-drinker 1.00 1.00
 <1 0.84 (0.83 to 0.86) 0.85 (0.83 to 0.86)
 1-2 0.82 (0.80 to 0.84) 0.82 (0.80 to 0.84)
 3-6 0.86 (0.84 to 0.89) 0.86 (0.84 to 0.88)
 7-9 1.21 (1.05 to 1.40) 1.12 (1.06 to 1.18)
 >9 1.46 (1.22 to 1.76) 1.17 (1.08 to 1.27)
Unplanned admissions in past 12 months:
 None 1.00 1.00
 1* 2.05 (1.99 to 2.11) 1.99 (1.94 to 2.04)
 2* 2.98 (2.85 to 3.11) 2.87 (2.76 to 2.98)
 ≥3* 4.69 (4.48 to 4.91) 4.22 (4.06 to 4.40)
Clinical and social characteristics:
 Atrial fibrillation 1.39 (1.37 to 1.42) 1.28 (1.26 to 1.30)
 Cancer* 1.91 (1.86 to 1.96) 2.05 (2.00 to 2.09)
 Asthma or chronic obstructive pulmonary disease 1.19 (1.17 to 1.22) 1.15 (1.13 to 1.18)
 Lives in care home* 1.80 (1.71 to 1.89) 1.61 (1.52 to 1.71)
 Congestive heart failure* 1.66 (1.60 to 1.72) 1.74 (1.69 to 1.79)
 Cardiovascular disease* 1.31 (1.28 to 1.34) 1.25 (1.22 to 1.27)
 Dementia* 2.61 (2.52 to 2.71) 2.34 (2.25 to 2.45)
 Epilepsy 1.22 (1.17 to 1.28) 1.25 (1.19 to 1.30)
 Learning disability 1.15 (1.10 to 1.19) 1.22 (1.16 to 1.28)
 Leg ulcer* 1.61 (1.55 to 1.68) 1.66 (1.60 to 1.73)
 Chronic liver disease or pancreatitis* 1.61 (1.48 to 1.74) 1.48 (1.39 to 1.58)
 Parkinson’s disease† 1.81 (1.73 to 1.88) 2.16 (2.05 to 2.28)
 Poor mobility* 1.63 (1.59 to 1.67) 1.59 (1.55 to 1.63)
 Rheumatoid arthritis 1.29 (1.25 to 1.34) 1.19 (1.13 to 1.24)
 Chronic kidney disease 1.97 (1.88 to 2.07) 1.86 (1.78 to 1.95)
 Type 1 diabetes 1.37 (1.28 to 1.46) 1.30 (1.22 to 1.38)
 Type 2 diabetes* 1.35 (1.31 to 1.38) 1.29 (1.26 to 1.32)
 Venous thromboembolism 1.19 (1.17 to 1.23) 1.16 (1.13 to 1.19)
Current prescribed drugs:
 Antipsychotics* 1.61 (1.54 to 1.69) 1.60 (1.52 to 1.68)
 Corticosteroids* 1.44 (1.40 to 1.48) 1.57 (1.52 to 1.61)
Clinical values:
 Anaemia (haemoglobin <110 g/L*) 1.93 (1.87 to 2.00) 2.10 (2.03 to 2.18)
 Abnormal liver function test result‡ 1.61 (1.52 to 1.70) 1.67 (1.61 to 1.75)
 High platelet count 1.36 (1.31 to 1.42) 1.38 (1.30 to 1.46)
Symptoms recorded in past 12 months:
 Appetite loss 1.30 (1.21 to 1.39) 1.35 (1.24 to 1.48)
 Dyspnoea* 1.33 (1.28 to 1.37) 1.28 (1.25 to 1.32)
 Weight loss 1.25 (1.20 to 1.31) 1.24 (1.17 to 1.31)
The model in women includes fractional polynomial terms for age (age−2 and age−2ln (age)) and body mass index (bmi−1 and bmi−5) and interactions with age for unplanned admissions, 
Townsend score, anaemia, abnormal liver function test result, type 2 diabetes, cardiovascular disease, heart failure, cancer, dementia, chronic kidney disease, chronic liver disease or 
pancreatitis, leg ulcer, poor mobility, care home residence, dyspnoea, corticosteroids, and antipsychotics.
The model in men includes fractional polynomial terms for age (age3 and age3ln (age)) and BMI (bmi−2 and bmi−2ln(bmi)) and interactions with age for unplanned admissions, Townsend score, 
anaemia, abnormal liver function test result, type 2 diabetes, cardiovascular disease, heart failure, cancer, dementia, chronic kidney disease, chronic liver disease or pancreatitis, leg ulcer, poor 
mobility, care home residence, dyspnoea, corticosteroids, antipsychotics, and Parkinson’s disease.
*Interaction with age, hazard ratios evaluated at mean age for men and women.
†interaction with age, hazard ratios evaluated at mean age for men only.
‡γ glutamyltransferase, alanine aminotransferase, or bilirubin levels more than three times the upper limit of normal.
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results were generally good except for over-prediction 
in Chinese women and under-prediction in black 
African women, although numbers of deaths were 
relatively small in these subgroups.
Decision curve analysis
Figure 5 displays the net benefit curves for the 
mortality equations at one year in men and women. 
These show that the prediction equations had higher 
net benefit than did strategies based on considering 
either no patients or all patients for intervention for 
risk thresholds up to around 50%.
Sensitivity and specificity
Table 5 shows the sensitivity, specificity, and positive 
and negative predictive values for the mortality 
equation at one year for various thresholds based on 
patients in the validation cohort.
Table 6 shows that the risk threshold for the top 
2%  at highest risk of death in the next year was 
47.0%, for the top 10% was 20.3%, and for the top 
50% was 2.9%. With a risk threshold of 20.3% over 
one year to identify the 10% of patients with the 
highest risk of death, the sensitivity for identifying 
deaths was 37.4%, specificity 97.3%, positive 
predictive value 46.0%, and negative predictive 
value 91.4%. Supplementary table 4 shows the 
results restricted to patients with two or more 
medical conditions.
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Fig 1 | Hazard ratios for all cause mortality in women by age
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Fig 2 | Hazard ratios for all cause mortality in men by age
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The corresponding thresholds for risk of unplanned 
hospital admission over one year were 60.7% to 
identify the top 2%, 34.0% for the top 10%, and 10.0% 
for the top 50% (results not shown).
Classification of frailty
Table 7 shows the characteristics of patients from the 
validation cohort split into four QFrailty groups that are 
broadly equivalent to the proportion of patients reported 
to be in the four categories according to the EFI.2
•  Group 1 represents severe frailty. This category 
includes 13 665 patients (ie, 2.74% of 499 478) 
who are either in the top 2% at highest risk of death 
in the next year or in the top 2% at highest risk of 
unplanned hospital admission.
•  Group 2 represents moderate frailty. This category 
includes 46 770 patients (ie, 9.36% of 499 478) who 
are either in the top 10% at highest risk of death in 
the next year or in the top 10% at highest risk of 
unplanned hospital admission (excluding those in 
the severe category).
•  Group 3 represents mild frailty. This category 
includes 215 253 patients (ie, 43.1% of 499 478) 
who are either in the top 50% at highest risk of death 
in the next year or in the top 50% at highest risk of 
unplanned hospital admission (excluding those in 
the severe and moderate categories).
•  Group 4 represents being “fit.” This category 
includes 223 790 patients (ie, 44.80% of 499 478) 
not in the above three categories.
For example, for those in the severe frailty category, 
the mean age is 86.1 years, 98.5% (n=13 460) have 
multimorbidity, 60.8% (n=8312) have poor mobility, 
61.3% (n=8373) have cardiovascular disease, 
50.5% (n=6895) have had falls, 46.2% (n=6310) 
have treated hypertension, 40.0% (n=5461) are 
taking antidepressants, 35.6% (n=4864) have atrial 
fibrillation, 34.8% (n=4756) have asthma or chronic 
Table 4 | Performance of QMortality algorithm to predict one year risk of death, and 
QAdmissions score to predict risk of unplanned admission over one year in men and 
women aged 65-100 years in validation cohort
Statistics
Mean (95% CI)
Women Men
QMortality score:
 D statistic 2.29 (2.27 to 2.31) 2.18 (2.16 to 2.20)
 Harrell’s C 0.853 (0.850 to 0.856) 0.844 (0.841 to 0.847)
 R2 (%) 55.6 (55.2 to 56.0) 53.1 (52.6 to 53.6)
QAdmissions score:
 D statistic 1.50 (1.49 to 1.51) 1.45 (1.44 to 1.46)
 Harrell’s C 0.757 (0.755 to 0.759) 0.751 (0.748 to 0.753)
 R2 (%) 34.9 (34.5 to 35.2) 33.5 (33.0 to 33.9)
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obstructive pulmonary disease, 32.8% (n=4484) have 
dementia, 28.7% (n=3925) have type 2 diabetes, 
25.1% (n=3436) have a diagnosis of cancer, 24.9% 
(n=3399) have anaemia, 19.9% (n=2724) have 
dyspnoea, 18.5% (n=2526) are taking anticoagulants, 
and 18.4% (n=2519) have peptic ulcer disease.
discussion
Recent NICE guidance on multiple morbidities3 
highlighted the need to develop new robust equations 
to identify patients in primary care with reduced 
life expectancy so that relevant assessments and 
interventions can be targeted appropriately. Existing 
equations to predict risk of death are based on biased 
samples, are insufficiently powered, fail to handle 
missing data appropriately, are poorly reported, or 
have poor performance to the extent that NICE has 
been unable to make a positive recommendation 
for any of the 41 models included in the review.3 We 
therefore developed and validated equations to predict 
absolute risk of death over the next year in men and 
women aged 65-100 years. The QMortality equations 
performed well on a separate validation cohort, 
with good levels of discrimination and calibration, 
improving on other equations used to predict all cause 
mortality.2334 The final model has good face validity 
as it includes demographic and clinical variables 
that clinicians would expect to affect mortality 
risk such as age, body mass index, deprivation, 
ethnicity, smoking status, alcohol intake, unplanned 
admissions in the past 12 months; atrial fibrillation, 
antipsychotics, cancer, asthma or chronic obstructive 
pulmonary disease, living in a care home, congestive 
heart failure, corticosteroids, cardiovascular disease, 
dementia, epilepsy, learning disability, leg ulcer, 
chronic liver disease or pancreatitis, Parkinson’s 
disease, poor mobility, rheumatoid arthritis, chronic 
renal disease, type 1 diabetes, type 2 diabetes, venous 
thromboembolism, anaemia, abnormal liver function 
test result, high platelet count, and visits to a doctor 
in the past year with either appetite loss, unexpected 
weight loss, or breathlessness.
Although the QMortality equation contains many 
variables, it is intended to be integrated into general 
practice computer systems where the extraction 
of data and risk calculation can be automated. We 
considered whether to develop a more parsimonious 
model with fewer predictors for use in other clinical 
settings but decided it would be preferable to have one 
model and for the user to select default values on the 
understanding that there may be a degree of under-
estimation or over-estimation of risk depending on the 
predictor in question.
Potential uses of the frailty classification and 
mortality index
In this study we have described a specific novel use 
for mortality estimates, which is to classify patients 
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Fig 5 | Decision curve analysis for women and men
Table 5 | Sensitivity, specificity, and positive and negative predictive values for death at different thresholds of predicted risk of death over one year in 
validation cohort
Threshold
Risk  
threshold %
True negative 
(count)
False negative 
(count)
False positive 
(count)
True positive 
(count) Sensitivity (%) Specificity (%)
Positive predictive 
value (%)
Negative predictive 
value (%)
Top 1% 58.3 436 007 58 477 2025 2969 4.8 99.5 59.5 88.2
Top 2% 47.0 433 741 55 748 4291 5698 9.3 99.0 57.0 88.6
Top 3% 40.2 431 282 53 212 6750 8234 13.4 98.5 55.0 89.0
Top 4% 35.4 428 786 50 713 9246 10 733 17.5 97.9 53.7 89.4
Top 5% 31.7 426 128 48 377 11 904 13 069 21.3 97.3 52.3 89.8
Top 10% 20.3 411 084 38 447 26 948 22 999 37.4 93.8 46.0 91.4
Top 15% 14.3 393 760 30 797 44 272 30 649 49.9 89.9 40.9 92.7
Top 20% 10.6 374 710 24 873 63 322 36 573 59.5 85.5 36.6 93.8
Top 25% 8.2 354 411 20 198 83 621 41 248 67.1 80.9 33.0 94.6
Top 30% 6.4 333 225 16 410 104 807 45 036 73.3 76.1 30.1 95.3
Top 35% 5.1 311 237 13 424 126 795 48 022 78.2 71.1 27.5 95.9
Top 40% 4.2 288 786 10 901 149 246 50 545 82.3 65.9 25.3 96.4
Top 45% 3.4 265 826 8887 172 206 52 559 85.5 60.7 23.4 96.8
Top 50% 2.9 242 548 7191 195 484 54 255 88.3 55.4 21.7 97.1
RESEARCH
12 doi: 10.1136/bmj.j4208 | BMJ 2017;358:j4208 | the bmj
Table 6 | Thresholds for classification of patients into one of four frailty groups
1 year risk of death*
1 year risk of unplanned hospital admission*
≥60.7% 34.1-60.6% 10.1-34.0% <10.1%
≥47.0% Severe frailty Severe frailty Severe frailty Severe frailty
20.3-46.9% Severe frailty Moderate frailty Moderate frailty Moderate frailty
2.9-20.2% Severe frailty Moderate frailty Mild frailty Mild frailty
<2.9% Severe frailty Moderate frailty Mild frailty Fit
Patients are classified according to the highest risk group. For example, a patient with a one year risk of death of 50% and a one year risk of unplanned 
admission of 8% would be classified in the severely frail group; a patient with a one year risk of death of 50% or a one year risk of unplanned admission 
of 62% would be classified in the severely frail group; and a patient with a 2% risk of death and a 5% risk of unplanned admission would be classified 
as “fit.”
*Risk thresholds correspond to highest 2%, 10%, and 50% absolute risks.
Table 7 | Characteristics of patients in validation cohort in each of the four frailty categories based on one year risk of unplanned admission or one 
year risk of death. Values are numbers (column percentages) unless stated otherwise
Characteristics
Group 1: severe 
frailty
Group 2: moderate 
frailty Group 3: mild frailty Group 4: fit
No of patients 13 665 46 770 215 253 223 790
Row % of total population 2.74 9.36 43.10 44.80
Men 6142 (44.9) 19 219 (41.1) 104 867 (48.7) 94 319 (42.1)
Mean (SD) age (years) 86.1 (8.4) 85.4 (7.6) 78.2 (6.7) 69.8 (3.9)
Mean (SD) Townsend deprivation score* 0.4 (3.0) 0.0 (3.0) −0.3 (2.9) −1.1 (2.7)
Mean (SD) body mass index 26.0 (5.8) 26.3 (5.4) 27.4 (5.2) 27.4 (4.6)
Age band (years):
 65-69 694 (5.1) 2032 (4.3) 26 606 (12.4) 121 904 (54.5)
 70-74 884 (6.5) 2849 (6.1) 37 271 (17.3) 69 881 (31.2)
 75-79 1316 (9.6) 4882 (10.4) 54 995 (25.5) 29 222 (13.1)
 80-84 2201 (16.1) 8468 (18.1) 57 188 (26.6) 2783 (1.2)
 ≥85 8570 (62.7) 28 539 (61.0) 39 193 (18.2) 0 (0)
Smoking status:
 Non-smoker 6000 (43.9) 23 560 (50.4) 104 320 (48.5) 133 214 (59.5)
 Former smoker 5936 (43.4) 18 503 (39.6) 84 077 (39.1) 72 028 (32.2)
 Light smoker 934 (6.8) 2686 (5.7) 14 853 (6.9) 10 598 (4.7)
  Moderate smoker 447 (3.3) 1189 (2.5) 7325 (3.4) 5238 (2.3)
 Heavy smoker 348 (2.5) 832 (1.8) 4678 (2.2) 2712 (1.2)
Alcohol intake (units/day):
 Non-drinker 9468 (69.3) 28 232 (60.4) 96 468 (44.8) 62 754 (28.0)
 <1 2486 (18.2) 10 752 (23.0) 62 990 (29.3) 79 192 (35.4)
 1-2 817 (6.0) 3924 (8.4) 25 892 (12.0) 38 876 (17.4)
  3-6 716 (5.2) 3325 (7.1) 26 157 (12.2) 39 692 (17.7)
  7-9 105 (0.8) 347 (0.7) 2524 (1.2) 2331 (1.0)
 >9 73 (0.5) 190 (0.4) 1222 (0.6) 945 (0.4)
Previous unplanned admissions in past 12 months:
 None 2888 (21.1) 25 293 (54.1) 189 282 (87.9) 222 311 (99.3)
 1 3856 (28.2) 13 040 (27.9) 21 480 (10.0) 1458 (0.7)
 2 2763 (20.2) 5280 (11.3) 3820 (1.8) 21 (0.0)
 ≥3 4158 (30.4) 3157 (6.8) 671 (0.3) 0 (0)
Clinical and social characteristics:
 Poor mobility 8312 (60.8) 18 188 (38.9) 24 622 (11.4) 4012 (1.8)
 Living in a residential or nursing home 2474 (18.1) 4419 (9.4) 2283 (1.1) 99 (0.0)
 Atrial fibrillation 4864 (35.6) 10 779 (23.0) 21 261 (9.9) 3825 (1.7)
 Any cancer 3436 (25.1) 9081 (19.4) 33 040 (15.3) 9618 (4.3)
 Asthma or chronic obstructive pulmonary disease 4756 (34.8) 11 697 (25.0) 41 269 (19.2) 18 748 (8.4)
 Congestive heart failure 3795 (27.8) 6585 (14.1) 8701 (4.0) 668 (0.3)
 Cardiovascular disease 8373 (61.3) 21 867 (46.8) 59 835 (27.8) 14 850 (6.6)
 Treated hypertension 6310 (46.2) 23 069 (49.3) 110 750 (51.5) 75 438 (33.7)
 Chronic kidney disease 1532 (11.2) 2912 (6.2) 4199 (2.0) 234 (0.1)
 Type 1 diabetes 358 (2.6) 697 (1.5) 1901 (0.9) 392 (0.2)
 Type 2 diabetes 3925 (28.7) 10 350 (22.1) 41 731 (19.4) 17 903 (8.0)
 Venous thromboembolism 1857 (13.6) 4300 (9.2) 10 768 (5.0) 3350 (1.5)
 Epilepsy 608 (4.4) 1349 (2.9) 3983 (1.9) 1579 (0.7)
 Leg ulcer 2036 (14.9) 4025 (8.6) 6851 (3.2) 1045 (0.5)
 Chronic liver disease or pancreatitis 535 (3.9) 954 (2.0) 2511 (1.2) 587 (0.3)
  Malabsorption (Crohn’s disease, ulcerative colitis, coeliac 
disease)
213 (1.6) 714 (1.5) 3107 (1.4) 2421 (1.1)
 Parkinson’s disease 850 (6.2) 1487 (3.2) 2549 (1.2) 422 (0.2)
 Peptic ulcer disease 2519 (18.4) 5778 (12.4) 16 121 (7.5) 6574 (2.9)
 Osteoporosis 2387 (17.5) 6401 (13.7) 16 969 (7.9) 8314 (3.7)
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into four frailty categories. This has been achieved 
by combining the one year predicted risk of death 
with the one year predicted risk of unplanned 
hospital admission to help identify the most severely 
frail patients for enhanced care packages to meet 
the immediate requirements of the UK General 
Medical Services contract. The most severe frailty 
category will identify patients with particularly high 
levels of morbidity who are at highest risk of death 
or unplanned hospital admission. This group of 
patients is likely to reflect elderly patients who are 
the most severely frail and who can be identified for 
focused assessment and intervention as part of the 
new General Medical Services contract in England. 
This includes falls assessment and drug review. The 
QMortality score could be used in conjunction with the 
QAdmissions score to allocate patients to one of four 
QFrailty categories. It could also be used recurrently to 
build and maintain practice based lists of patients with 
different levels of frailty or mortality risks over time. 
This could be done as an automated procedure using 
electronic health records.
The models can also be used in a face-to-face 
consultation between the patient and clinician with 
the intention of sharing the information with the 
patient to assess management options. The decision 
curve analysis shows there is a higher net benefit 
for the prediction models than strategies based on 
considering either no patients or all patients for 
intervention for risk thresholds up to around 50%. 
Mortality estimates including cancer stage and grade 
are already used to help patients with cancer to weigh 
up the risks and benefits of surgery, chemotherapy, 
and radiotherapy.35 Patients with a high risk of death 
in the near future may choose to decline aggressive 
treatments or defer preventive treatments, screening 
interventions, or interventions for asymptomatic 
conditions.36 Mortality estimates could also be used to 
help guide the introduction and addition of palliative 
care to help plan end of life care.37 For example, 
six month mortality estimates in the United States 
are used to trigger Advance Care Planning and also 
to determine access to hospice services under the 
Medicare scheme.38 They are also used to improve 
self awareness of health status; to measure, monitor, 
and compare outcomes between different healthcare 
providers36; and are used by governments to decrease 
the burden of certain risk factors at a population 
level.34
Ethical considerations
We see an important distinction between factors that 
are included in a risk equation to ensure that the risk 
estimates are as accurate as possible and how the risk 
equation is then used in guidelines and clinical practice 
to ensure ethical, effective, and equitable access to 
services for everyone. The primary purpose of our 
paper is to report on the development and validation 
of new risk equations rather than to produce national 
policy or clinical guidance, although we recognise the 
results may be used by policy makers and clinicians. 
All clinical decisions about the beneficial and safe 
use of these risk equations necessarily remain the 
responsibility of the attending clinician. However, there 
are ethical issues to consider about how the tools might 
be used. We have analysed this within the “four ethical 
principles” framework, which is widely used in medical 
decision making. The four principles are autonomy, 
beneficence, justice, and non-maleficence.39 The new 
risk equations, when implemented in clinical software, 
Table 7 | Continued
Characteristics
Group 1: severe 
frailty
Group 2: moderate 
frailty Group 3: mild frailty Group 4: fit
 Rheumatoid arthritis 680 (5.0) 1617 (3.5) 5447 (2.5) 2568 (1.1)
 Learning disability 803 (5.9) 1507 (3.2) 2110 (1.0) 562 (0.3)
 Dementia 4484 (32.8) 9726 (20.8) 8251 (3.8) 249 (0.1)
 Bipolar disorder or schizophrenia 306 (2.2) 727 (1.6) 2444 (1.1) 784 (0.4)
 Registered blind or impaired vision 1287 (9.4) 3148 (6.7) 5422 (2.5) 1352 (0.6)
 Falls 6895 (50.5) 16 789 (35.9) 33 768 (15.7) 12 217 (5.5)
Current prescribed drugs:
 Anticoagulants 2526 (18.5) 7238 (15.5) 18 577 (8.6) 3102 (1.4)
 Antidepressants 5461 (40.0) 15 267 (32.6) 50 687 (23.5) 24 707 (11.0)
 Antipsychotics 1524 (11.2) 2666 (5.7) 3947 (1.8) 648 (0.3)
 Corticosteroids 3615 (26.5) 8761 (18.7) 27 963 (13.0) 5993 (2.7)
 Non-steroidal anti-inflammatory drugs 717 (5.2) 3636 (7.8) 37 369 (17.4) 47 524 (21.2)
Symptoms recorded in past 12 months:
 Appetite loss 267 (2.0) 362 (0.8) 410 (0.2) 67 (0.0)
 Weight loss 564 (4.1) 947 (2.0) 1611 (0.7) 419 (0.2)
 Dyspnoea 2724 (19.9) 6811 (14.6) 21 783 (10.1) 4998 (2.2)
 Syncope 750 (5.5) 1380 (3.0) 2461 (1.1) 854 (0.4)
 Urinary incontinence 550 (4.0) 1047 (2.2) 2314 (1.1) 934 (0.4)
 Urinary retention 353 (2.6) 453 (1.0) 670 (0.3) 157 (0.1)
Clinical values:
 Anaemia (haemoglobin <110 g/L) 3399 (24.9) 5322 (11.4) 6572 (3.1) 792 (0.4)
 Abnormal liver function test result 998 (7.3) 1853 (4.0) 5559 (2.6) 1518 (0.7)
 High platelet count 523 (3.8) 1027 (2.2) 2399 (1.1) 804 (0.4)
*This is an area level continuous score based on patients’ postcode. A higher Townsend score implies a greater level of deprivation.
RESEARCH
14 doi: 10.1136/bmj.j4208 | BMJ 2017;358:j4208 | the bmj
are designed to provide more accurate information for 
patients and clinicians on which to base decisions, 
thereby promoting shared decision making and patient 
autonomy. They are intended to result in clinical benefit 
by identifying where changes in management are likely 
to benefit patients, thereby promoting the principle of 
beneficence. Justice can be achieved by ensuring that 
the use of the risk equations results in fair and equitable 
access to health services that are commensurate with 
the patients’ level of risk. Lastly, the risk assessment 
must not be used in a way that causes harm either to 
the individual patient or to others (for example, by 
introducing or withdrawing treatments where this is 
not in the patients’ best interest) thereby supporting 
the non-maleficence principle. How this applies 
in clinical practice will naturally depend on many 
factors, especially the patient’s wishes, the evidence 
base for any interventions, the clinician’s experience, 
national priorities, and the available resources. The 
risk assessment equations therefore supplement 
clinical decision making, not replace it.
Comparison with the other risk scores
A recent review of 41 mortality risk scores reported in 
24 research papers failed to identify any that could 
be reliably used to predict mortality in a community 
settitng.3 Of the studies reviewed, the Charleston 
comorbidity index, which consists of 23 variables, 
achieved the best C statistic, with a value of 0.77 in 
the internal validation cohort and 0.80 in the external 
validation cohort.3 40 Other studies have used risk 
scores to predict mortality, such as the John Hopkins 
Aggregated Diagnostic Groups (ADG) score41 and the 
Hospital-patient One-year Mortality Risk (HOMR) 
score.36 The HOMR score consists of 12 patient 
variables and eight hospital admission factors and was 
designed to predict one year mortality risk in adults 
aged 18-100 years admitted to hospital. It includes 
fractional polynomial terms for continuous variables 
and interactions between statistically significant 
predictors. The HOMR score has excellent calibration 
and discrimination, with a C statistic of 0.92, although 
this may reflect the much wider age range in the HOMR 
study. The ADG score consists of 30 variables and has 
been validated using a community based sample. 
However, the C statistic was lower (0.81) than the 
values for the QMortality score (0.84 in men and 0.85 
in women), and the ADG equation is not published or 
freely available.41
The electronic frailty index (EFI) is a simple 
unweighted count of the number of “deficits” a 
patient has out of a total of 36, where a deficit 
is a physical disability or social vulnerability as 
identified by a consensus panel.2 The EFI has also 
been used to predict mortality in a UK community 
based population, although performance (based 
on standard definitions42) was poor or fair, with a C 
statistic of 0.66 on an internal validation cohort and 
0.76 on an external validation cohort.2 The EFI also 
had extremely low levels of explained variation in 
time to death of 0.02-0.04%,2 whereas the QMortality 
scores explained 53% and 55% of the variation in 
men and women, respectively. The EFI equation has 
not been published and it does not appear to include 
continuous variables such as age. The QMortality and 
QAdmissions equations include all the factors in the 
EFI, where these predicted either risk of death or risk 
of unplanned hospital admission. Unlike the EFI, our 
equations include further key determinants of death 
and unplanned admissions, such as age, sex, ethnic 
group, smoking status, alcohol intake, deprivation, 
and previous unplanned admissions, and also include 
major conditions—cancer, epilepsy, serious mental 
illness, chronic liver disease, inflammatory bowel 
disease, learning disability, specific drug treatments—
which are all relevant to risk of outcomes and for which 
patients are likely to need ongoing careful assessment. 
Our multivariable analysis has allowed us to attribute 
appropriate weights to each factor and incorporate 
interactions between age and different medical 
conditions. This means, for example, that a patient 
who is 65 years old with three medical conditions will 
have a different absolute risk of death or unplanned 
hospital admission than a patient with the same 
conditions but who is aged 95 years.
Methodological considerations
The methods to derive and validate these models 
are broadly the same as for a range of other clinical 
risk prediction tools derived from the QResearch 
database.7 8 12 43 44 The strengths and limitations of the 
approach have already been discussed in detail.7 14 43 45-47 
In summary, key strengths include size, duration of 
follow-up, representativeness, and lack of selection, 
recall, and respondent bias. UK general practices have 
good levels of accuracy and completeness in recording 
clinical diagnoses and prescribed drugs.48 We think 
our study has good face validity since it has been 
conducted in the setting where most patients in the 
UK are assessed, treated, and followed up. Limitations 
of our study include the lack of formal adjudication 
of diagnoses, information bias, and potential for 
bias owing to missing data. Our database has linked 
hospital admissions data and is therefore likely to have 
picked up the majority of hospital admissions, thereby 
minimising ascertainment bias. We focused on two 
hard outcomes to identify frail patients (unplanned 
admissions and mortality) rather than admission to a 
nursing home or decline in function, as both of these 
are more difficult to measure using electronic health 
records. Also, for simplicity we grouped all cancers 
together as a single variable rather than distinguish 
between different types of cancer and account for 
grade and stage. This was a pragmatic decision, partly 
driven by the lack of information in general practice 
records about grade and stage of cancer and the 
availability of existing purpose designed tools such as 
the QCancer prognostic scores.49 QMortality will tend 
to have under-estimated mortality risk in those with 
a late stage cancer (for example) and over-estimated 
it in patients with an early stage cancer. We excluded 
patients without a deprivation score since this group 
RESEARCH
the bmj | BMJ 2017;358:j4208 | doi: 10.1136/bmj.j4208 15
may represent a more transient population where 
follow-up could be unreliable or unrepresentative. 
Their deprivation scores are unlikely to be missing at 
random so we did not think it would be appropriate to 
impute them.
We have presented sensitivity and specificity values 
for death at a range of centile values and combined 
predicted risks of death and unplanned hospital 
admissions into frailty categories that can be used to 
identify patients who are most severely frail based on 
their risk of clinically important outcomes. The present 
validation has been done on a separate set of practices 
and individuals to those that were used to develop the 
score, although the practices all use the same general 
practice clinical computer system (EMIS, used by 
55% of UK general practitioners). An independent 
validation study would be a more stringent test and 
should be done, but when such independent studies 
have examined other risk equations46 47 50 51 they 
have shown similar performance compared with 
the validation in the QResearch database.12 43 45 We 
have not been able to undertake direct comparisons 
between the QMortality score and the ADG, EFI, and 
HOMR scores since these are not publicly available. 
For transparency, we have published the source code 
of the QMortality equation on the QAdmissions website 
(www.qadmissions.org) alongside the QAdmissions 
equation. The rationale for this is to ensure that those 
interested in reviewing or using the open source will 
then be able to find the latest available version as the 
score continues to be updated. Lastly, our study was 
not designed to compare the performance of QMortality 
scores against clinical judgment alone, although we 
have provided sufficient information to enable other 
researchers to undertake such a study. Freund et al 
found that predictive modelling software was more 
effective at identifying patients at increased risk of 
hospital admission and death than clinical judgment 
alone.52 However, clinicians may be more effective at 
identifying those for whom preventive services may 
have a better impact.52 53
Conclusion
We have developed a new equation to quantify 
absolute risk of death within the next year in people 
aged 65 or more, taking account of demographic, 
social, and clinical variables. The equation provides a 
valid measure of absolute risk of death in the general 
population of patients aged 65 or more as shown by 
the performance in a separate validation cohort. 
The equation can be used in conjunction with the 
QAdmissions equation to classify patients into four 
QFrailty groups to enable their identification for 
focused assessments and interventions.
A simple web calculator can be used to implement the QMortality 
algorithm (http://qmortality.org), which will be publicly available 
alongside the paper. It also has the open source software for 
download. A web calculator to implement the combined QMortality 
and QAdmissions calculator to derive the four frailty categories is 
available here http://qfrailty.org.
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